From discovery to preparedness: reframing antimicrobial resistance as a global governance challenge
- 1College of Health Sciences, VinUniversity , ,
Abstract
Almost a century after the discovery of penicillin, the antimicrobial resistance (AMR) crisis has become as much a failure of global governance as a biomedical challenge. Published Global Burden of Disease estimates for 2000–2021 show a persistent geographic hierarchy of mortality, a pattern consistent with AMR burden being embedded in health system capacity rather than due to pathogen evolution alone. Furthermore, the for-profit pharmaceutical model remains structurally misaligned with the clinical necessity of restricted antibiotic use. This Perspective argues that the next phase of AMR mitigation must pivot from a discovery-dominated paradigm to an integrated preparedness model in which innovation, stewardship, surveillance, and governance are collectively strengthened. We contend that success will be determined less by laboratory and technology breakthroughs than by the political commitment to decouple revenue from sales volume and to govern antimicrobial effectiveness as a shared, exhaustible resource. We propose a coordinated policy toolkit — integrating “push-pull” incentives and One Health surveillance — to protect the epidemiological utility of these finite resources. The antibiotics era began as a story of discovery, became a story of complacency, and must now become a story of stewardship and global governance.
Related
- Agricultural governance to strengthen the multisectoral response to antimicrobial resistance: the experience of Bolivia.
- Antimicrobial Resistance and One Health: Lessons on One Health Governance and Implementation from the Fleming Fund.
- Comprehensive Review: Governance of Antimicrobial Resistance in Nigerian Healthcare Settings
- Stakeholder perceptions of antimicrobial resistance governance in livestock production: a cross-sectional study from North-Central Nigeria.
- Artificial Intelligence in the Fight Against Antimicrobial Resistance: Applications in Diagnosis, Susceptibility Prediction, Precision Dosing, and Antibiotic Discovery.
BibTeX
@article{nguyen2026from,
title = {{From discovery to preparedness: reframing antimicrobial resistance as a global governance challenge}},
author = {Quan Khoi Nguyen and Jeffrey D. Mayne and Andrew W. Taylor-Robinson},
journal = {Frontiers in public health},
year = {2026},
month = oct,
doi = {10.3389/fpubh.2026.1965508},
url = {https://europepmc.org/article/PMC/PMC13668851},
note = {CC BY},
}
RIS
TY - JOUR
TI - From discovery to preparedness: reframing antimicrobial resistance as a global governance challenge
AU - Quan Khoi Nguyen
AU - Jeffrey D. Mayne
AU - Andrew W. Taylor-Robinson
PY - 2026
DA - 2026/10/01
JO - Frontiers in public health
DO - 10.3389/fpubh.2026.1965508
UR - https://europepmc.org/article/PMC/PMC13668851
AB - Almost a century after the discovery of penicillin, the antimicrobial resistance (AMR) crisis has become as much a failure of global governance as a biomedical challenge. Published Global Burden of Disease estimates for 2000–2021 show a persistent geographic hierarchy of mortality, a pattern consistent with AMR burden being embedded in health system capacity rather than due to pathogen evolution alone. Furthermore, the for-profit pharmaceutical model remains structurally misaligned with the clinical necessity of restricted antibiotic use. This Perspective argues that the next phase of AMR mitigation must pivot from a discovery-dominated paradigm to an integrated preparedness model in which innovation, stewardship, surveillance, and governance are collectively strengthened. We contend that success will be determined less by laboratory and technology breakthroughs than by the political commitment to decouple revenue from sales volume and to govern antimicrobial effectiveness as a shared, exhaustible resource. We propose a coordinated policy toolkit — integrating “push-pull” incentives and One Health surveillance — to protect the epidemiological utility of these finite resources. The antibiotics era began as a story of discovery, became a story of complacency, and must now become a story of stewardship and global governance.
SN - 2296-2565
ER -